China SXT Pharmaceuticals, Inc. | Micro-cap | Healthcare
$1.65
3.12%
| China SXT Stock Comparison:
China SXT vs Haleon Plc - ADRChina SXT vs United TherapeuticsChina SXT vs IronwoodChina SXT vs BioAge LabsChina SXT vs Journey MedicalChina SXT vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 21.7M
Total Liabilities 6.2M
Shareholders Equity 15.4M
Debt to Equity 0.40

Cash Flow Metrics

Revenue & Profitability Trend

China SXT Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i1.7M1.9M2.0M2.6M4.8M
Cost of Goods Sold i1.4M1.4M1.5M1.4M1.9M
Gross Profit i367.4K554.0K426.3K1.3M2.8M
Gross Margin % i21.1%28.7%21.6%48.1%59.4%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i3.0M3.1M6.0M6.4M5.0M
Other Operating Expenses i-----
Total Operating Expenses i3.0M3.1M6.0M6.4M5.0M
Operating Income i-2.7M-2.5M-5.6M-5.2M-2.2M
Operating Margin % i-154.0%-130.4%-284.4%-199.4%-46.0%
Non-Operating Items
Interest Income i-----
Interest Expense i648.2K544.3K476.8K36.7K-
Other Non-Operating Income25.0K-39.0K149.5K-181.6K871.6K
Pre-tax Income i-3.3M-3.1M-5.9M-5.4M-2.9M
Income Tax i000328.1K-192.7K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-3.3M-3.1M-5.9M-5.7M-2.7M
Net Margin % i-189.8%-160.7%-301.0%-220.4%-57.5%
Key Metrics
EBITDA i-2.6M-2.4M-5.2M-5.1M-1.9M
EPS (Basic) i-$-28.58$-177.84$-137.92$-95.48
EPS (Diluted) i-$-28.58$-177.84$-137.92$-95.48
Basic Shares Outstanding i-108428333724159128781
Diluted Shares Outstanding i-108428333724159128781

Income Statement Trend

China SXT Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i18.1M12.1M17.4M15.5M13.3M
Short-term Investments i-----
Accounts Receivable i1.3M1.3M1.3M3.3M4.5M
Inventory i828.1K794.9K531.3K1.0M859.7K
Other Current Assets---288.9K180.4K
Total Current Assets i21.3M14.2M19.5M22.5M23.2M
Non-Current Assets
Property, Plant & Equipment i143.3K144.0K151.4K164.1K158.7K
Goodwill i11.8K19.1K27.9K38.8K45.8K
Intangible Assets i11.8K19.1K27.9K38.8K45.8K
Long-term Investments-----
Other Non-Current Assets---0321.4K
Total Non-Current Assets i367.0K8.9M10.0M11.1M11.3M
Total Assets i21.7M23.1M29.6M33.5M34.5M
Liabilities
Current Liabilities
Accounts Payable i1.2M1.3M1.4M1.5M1.5M
Short-term Debt i772.2K2.4M3.4M2.0M37.1K
Current Portion of Long-term Debt-----
Other Current Liabilities674.4K361.5K789.2K1.2M819.7K
Total Current Liabilities i6.0M8.9M14.5M17.1M18.6M
Non-Current Liabilities
Long-term Debt i211.7K294.7K365.8K06.3K
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i211.7K294.7K365.8K06.3K
Total Liabilities i6.2M9.2M14.9M17.1M18.6M
Equity
Common Stock i44.5M4.4M913.8K162.5K62.1K
Retained Earnings i-28.0M-24.7M-21.6M-15.7M-10.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i15.4M13.9M14.7M16.4M16.0M
Key Metrics
Total Debt i983.9K2.6M3.8M2.0M43.4K
Working Capital i15.3M5.3M5.0M5.3M4.7M

Balance Sheet Composition

China SXT Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i-3.3M-3.1M-5.9M-5.7M-2.7M
Depreciation & Amortization i82.3K203.2K250.2K320.0K345.4K
Stock-Based Compensation i0352.1K554.6K2.3M0
Working Capital Changes i-966.8K-358.6K1.4M45.6K-806.5K
Operating Cash Flow i-2.6M-2.5M-3.3M-2.1M-2.3M
Investing Activities
Capital Expenditures i63.5K-7.1K-70.7K-62.5K-93.0K
Acquisitions i-----
Investment Purchases i--00-8.8M
Investment Sales i-----
Investing Cash Flow i63.5K26.4K-12.3K-46.9K-5.8M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i1.9M1.5M4.0M2.8M0
Debt Repayment i-1.9M-78.7K-26.1K-33.1K-124.9K
Financing Cash Flow i8.4M-2.6M2.9M1.6M12.3M
Free Cash Flow i-2.3M-1.9M-151.4K205.8K-1.4M
Net Change in Cash i5.9M-5.1M-357.4K-541.6K4.2M

Cash Flow Trend

China SXT Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 0.01
Price to Book 1.44
Price to Sales 108.64

Profitability Ratios

Profit Margin -189.77%
Operating Margin -224.07%
Return on Equity -22.50%
Return on Assets -7.48%

Financial Health

Current Ratio 3.54
Debt to Equity 6.37
Beta 1.36

Per Share Data

EPS (TTM) $-2.31
Book Value per Share $1.12
Revenue per Share $1.22

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
sxtc183.3M0.011.44-22.50%-189.77%6.37
Haleon Plc - ADR 41.7B19.935.089.38%13.81%53.41
United Therapeutics 19.3B16.922.6819.30%40.36%0.00
Ironwood 230.7M92.69-0.73-0.29%-2.56%-1.94
BioAge Labs 212.2M-0.890.72-35.88%0.00%2.97
Journey Medical 186.8M39.088.66-57.22%-15.49%131.34

Financial data is updated regularly. All figures are in the company's reporting currency.